#1 Clinical Trials Search in Europe

Adeno-Associated Virus Serotype 9 Expressing The Human Fukutin Related Protein And Target Sequence Of The Mir-208A

A groundbreaking clinical trial is underway to evaluate a new gene therapy treatment for patients with limb-girdle muscular dystrophy (LGMDR9). The study focuses on using an adeno-associated virus serotype 9 (AAV9) vector carrying the FKRP gene, known as GNT0006. This trial aims to assess the safety, tolerability, and efficacy of this innovative approach in treating LGMDR9, offering hope for patients affected by this rare genetic disorder.

Table of Contents

What is GNT0006?

GNT0006 is a new gene therapy being developed to treat a specific type of muscular dystrophy called LGMDR9 (formerly known as LGMD2I)[1]. It is classified as an adeno-associated viral vector therapy, which means it uses a harmless virus to deliver a corrective gene to the patient’s cells[1].

The full scientific name of this therapy is “ADENO-ASSOCIATED VIRUS SEROTYPE 9 EXPRESSING THE HUMAN FUKUTIN RELATED PROTEIN AND TARGET SEQUENCE OF THE MIR-208A”[1]. This long name describes the key components of the therapy:

  • Adeno-associated virus serotype 9: The harmless virus used to deliver the gene
  • Human Fukutin Related Protein (FKRP): The corrective gene being delivered
  • MIR-208A: A specific genetic sequence that helps control how the therapy works

Target Condition: LGMDR9

LGMDR9 is a type of limb-girdle muscular dystrophy. This is a genetic condition that causes progressive muscle weakness, primarily affecting the muscles around the shoulders and hips[1]. People with LGMDR9 have mutations in the FKRP gene, which leads to problems with muscle function and strength.

How GNT0006 Works

GNT0006 is designed to treat LGMDR9 by delivering a correct copy of the FKRP gene to the patient’s cells[1]. The therapy is given as a single intravenous injection, meaning it’s delivered directly into the bloodstream. Once in the body, the harmless virus carries the corrective gene to the muscles, where it can potentially help restore proper muscle function.

Clinical Trial Overview

A clinical trial is currently underway to test the safety and effectiveness of GNT0006[1]. This trial is divided into two stages:

  1. Stage 1 (Dose Escalation Phase): This stage will involve 6 patients over 16 years old. They will be divided into two groups, each receiving a different dose of GNT0006.
  2. Stage 2 (Randomized Placebo-Controlled Phase): This stage will involve 33 patients over 16 years old. Some patients will receive GNT0006, while others will receive a placebo (a harmless substance with no active ingredients).

Eligibility Criteria

To participate in this trial, patients must meet certain criteria[1]. Some key requirements include:

  • Being at least 16 years old
  • Having a confirmed diagnosis of LGMDR9
  • Being able to walk short distances (with assistance if needed)
  • Having some breathing difficulties, but not severe

There are also several factors that would prevent someone from participating, such as having certain other medical conditions or previous gene therapy treatments.

Trial Objectives

The main goals of this clinical trial are[1]:

  1. To determine if GNT0006 is safe for patients with LGMDR9
  2. To find the best dose of GNT0006
  3. To see if GNT0006 can improve muscle function and breathing in patients with LGMDR9

Potential Benefits

If successful, GNT0006 could potentially[1]:

  • Improve muscle strength and function
  • Enhance breathing capacity
  • Slow down or stop the progression of LGMDR9
  • Improve quality of life for patients with this condition

Safety Considerations

As with any new treatment, there are potential risks and side effects that are not yet fully known[1]. The clinical trial is designed to carefully monitor patients for any adverse effects. Some safety measures in place include:

  • Careful screening of participants
  • Regular medical check-ups and tests throughout the trial
  • A phased approach, starting with lower doses before moving to higher doses

It’s important to note that GNT0006 is still in the experimental stage. While it shows promise, more research is needed to fully understand its effectiveness and safety for treating LGMDR9.

Aspect Details
Trial Name GNT0006 gene therapy trial in patients with limb-girdle muscular dystrophy
Condition FKRP-related limb-girdle muscular dystrophy (LGMDR9)
Intervention Intravenous administration of GNT0006 (AAV9 vector carrying FKRP gene)
Trial Design Phase 1/2, two-stage study (dose escalation and randomized placebo-controlled)
Primary Outcome Change in FVC% at one year post-treatment
Key Eligibility Criteria Ambulant patients ≥16 years old, confirmed LGMDR9 diagnosis, FVC 40-80%
Follow-up Duration Up to 5 years after active treatment

FAQ

  • What is the purpose of this clinical trial? The trial aims to evaluate the safety, tolerability, and efficacy of GNT0006, a gene therapy treatment for patients with FKRP-related limb-girdle muscular dystrophy (LGMDR9). It involves intravenous administration of an adeno-associated virus carrying the FKRP gene.
  • Who is eligible to participate in this trial? Eligible participants are ambulant male or female patients at least 16 years old with a documented LGMDR9 diagnosis. They must be able to perform specific physical tasks and have a forced vital capacity between 40% and 80% of the expected value.
  • How is the trial structured? The trial is divided into two stages. Stage 1 is a dose escalation phase with two cohorts receiving different doses of GNT0006. Stage 2 is a randomized, placebo-controlled phase involving 33 patients to assess the efficacy of the selected dose.
  • What is the primary outcome measure of the trial? The primary endpoint is the change from baseline in forced vital capacity (FVC%) in sitting position at one year post-treatment, comparing the treated group to the placebo group in Stage 2 of the trial.
  • How long will participants be followed after receiving the treatment? All participants will be followed for up to 5 years after receiving the active treatment (GNT0006) to assess long-term safety and efficacy.

Ongoing Clinical Trials on Adeno-Associated Virus Serotype 9 Expressing The Human Fukutin Related Protein And Target Sequence Of The Mir-208A

  • Gene Therapy Study for Patients with Limb-Girdle Muscular Dystrophy Using GNT0006

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Denmark France

Glossary

  • Adeno-Associated Virus (AAV): A small virus that infects humans and some other primate species without causing disease. AAVs are often used as vectors in gene therapy to deliver genetic material into cells.
  • FKRP gene: The Fukutin-Related Protein gene, which when mutated, causes certain types of muscular dystrophy, including LGMDR9.
  • Limb-Girdle Muscular Dystrophy (LGMDR9): A genetic disorder characterized by progressive muscle weakness and wasting, primarily affecting the shoulders, upper arms, pelvic area, and thighs.
  • Gene therapy: A technique that uses genes to treat or prevent disease. In this case, it involves delivering a healthy copy of the FKRP gene to cells using an AAV vector.
  • Forced Vital Capacity (FVC): The total amount of air exhaled during a forced breath, used to assess lung function and respiratory muscle strength.
  • Intravenous administration: Delivery of a substance directly into a vein, allowing it to enter the bloodstream immediately.
  • Placebo: An inactive substance or treatment used in clinical trials to compare the effects of a new drug or therapy.
  • Vector: In gene therapy, a vehicle used to deliver genetic material into cells. In this trial, AAV9 is used as the vector.

References

  1. http://clinicaltrials.eu/trial/gene-therapy-study-for-patients-with-limb-girdle-muscular-dystrophy-using-gnt0006/